X

Trial Profile

ENTYVIO Real-World Outcomes in Bio-naïve Crohn's Disease Patients in Belgium, Australia, and Switzerland: An EVOLVE Observational Expansion Study

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 12 May 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ustekinumab (Primary) ; Vedolizumab (Primary)
Indications Crohn's disease
Focus Therapeutic Use
Acronyms EVOLVE; EVOLVE Expansion study
Sponsors Takeda

Most Recent Events

10 May 2023 Primary endpoint (Cumulative Rates of Clinical Remission Over 36 Months Compared Between VDZ and UST Cohorts) has not been met.
10 May 2023 According to a Takeda media release, the data from this study was presented as an oral presentation at Digestive Disease Week (DDW) 2023 in Chicago, IL.
10 May 2023 Results assessing efficacy and safety presented in a Takeda media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com